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Abstract
Obesity is a significant risk factor for endometrial cancer, the most common gynecologic
malignancy in the United States, but much remains unclear about the relationship between
obesity-related factors and the development of endometrial cancer. Omentin, a recently
discovered adipokine, has been shown to be present in lower levels in patients who are
obese and/or insulin resistant. A case-control study was conducted using the serum of 140
women with endometrial cancer and 75 women with endometrial hyperplasia who were
matched 1:1 based on body mass index (BMI) and menopausal status to women with no
history of endometrial cancer (controls). The concentration of omentin in the patients’ serum
was experimentally determined by conducting tests in triplicate on an enzyme-linked
immunoadsorbent assay (ELISA) specific to human omentin. The mean serum omentin
levels of women with endometrial hyperplasia and endometrial cancer were statistically
significantly lower than controls, regardless of BMI. The mechanism that induces this
change remains unknown, but these results present exciting promise for omentin’s use as a
biomarker and role in understanding the relationship between obesity-related factors and
endometrial carcinoma.
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Background and Introduction
Endometrial Adenocarcinoma
Endometrial cancer is a malignant process that arises from the inner lining
of the uterus (endometrium). It is the fourth most common cancer among women
in the United States and the most frequently diagnosed gynecologic malignancy.
In 2014, more than 52,000 American women will be diagnosed with the
disease.[1]
Endometrial cancer is most commonly diagnosed in postmenopausal
women, with a median age at diagnosis of 62 years. While white women are
most likely to develop the disease compared to other races, black women are
most likely to die from the disease (Table 1).[2] Reasons for this disparity are
unclear.

Race

New Cases

Deaths

White

25.4

4.0

Black

23.2

7.5

Asian

19.1

2.7

Native American

20.0

3.4

Hispanic

19.8

3.4

Table 1: Endometrial Cancer Cases and Deaths per 100,000
People[2]. Number of cases and deaths by race in 2014.
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Histologically, endometrial cancer is classically divided into two
categories: type I and type II. Type I tumors account for up to 85% of
endometrial cancers and are defined as grade 1 or grade 2 endometrioid
endometrial cancers. Most of these tumors are diagnosed at an early stage and
therefore confer a favorable prognosis. Of interest, type I endometrial cancers
are estrogen-dependent and often develop in the setting of complex atypical
hyperplasia of the endometrium. Aberrations in PTEN and K-ras are commonly
found in type I tumors.[3] In contrast, type II endometrial cancers are high grade
and are more likely to be diagnosed at an advanced stage. They have no known
precursor lesion. As such, type II endometrial cancer often has a poor prognosis.
Mutations in p53 are frequently identified in these tumors.[4]
The strongest risk factor for type I endometrial cancer is unopposed
estrogen therapy, with a relative risk of 10-20. While unopposed estrogen may
be due to exogenous estrogen, such as hormone replacement therapy or
tamoxifen, it is more commonly due to excess endogenous estrogen. Several
factors can increase endogenous estrogen, including chronic anovulation (such
as in patients with polycystic ovarian syndrome or PCOS), an estrogen-producing
tumor, or obesity. Of these, however, obesity confers the greatest risk.[5]
Studies have found that obesity confers up to a five-fold risk of developing
endometrial cancer when compared to normal-weight women.[6] Other risk
factors for type I tumors include advanced age, diabetes, and hypertension, and
some genetic syndromes, such as Lynch Syndrome. The risk factors for type II
tumors are not well understood.
2

Early stage endometrial cancer is highly curable, with 5-year survival rates
approaching 90% for patients with stage I malignancies.[7] In fact, many women
with early stage, grade 1 or 2, endometrioid, endometrial cancer will be cured
with surgical resection alone. However, the majority of patients who recur are
incurable, with an average survival of only six to eighteen months.[8]
There are currently no prognostic biomarkers for endometrial cancer
consistently utilized in clinical practice. However, multiple markers have been
associated with prognosis in studies.

For example, expression of EGFR in

endometrioid tumors has been found to predict a decrease in survival by up to
20% from patients without EGFR expression.[9] Other potential markers of poor
prognosis include p53 overexpression, DNA methylation, and increased Ki-67
staining.

Expression of estrogen and progesterone receptors has been

associated with improved prognosis.[10]
Endometrial Hyperplasia
Endometrial hyperplasia is a benign overgrowth, or proliferation, of glands
in the endometrium. It is also most commonly diagnosed in postmenopausal
women. As the precursor lesion to type I endometrial cancers, it has similar risk
factors with obesity as the most significant risk factor.
In an attempt to classify hyperplasia, the World Health Organization
(WHO) has divided endometrial hyperplasia into four categories based upon the
glandular and stromal pattern of the endometrium and the presence or absence
of nuclear atypia. These four categories are simple hyperplasia without atypia,
3

complex hyperplasia without atypia, simple hyperplasia with atypia, and complex
hyperplasia with atypia.[11] Though all patients with endometrial hyperplasia
have a risk of developing endometrial cancer, some histologic subtypes have a
greater risk than others. The WHO classification system correlates well with this
risk (Table 2).[12]
WHO Classification

Incidence of Endometrial Cancer

Simple Hyperplasia without Atypia

1%

Simple Hyperplasia with Atypia

3%

Complex Hyperplasia without Atypia

8%

Complex Hyperplasia with Atypia

29%

Table 2: Incidence of Endometrial Cancer by WHO Hyperplasia
Category[12]. Categories of hyperplasia ranked by risk of endometrial
cancer development.
Of all subtypes of endometrial hyperplasia, complex atypical hyperplasia
confers the greatest risk of developing cancer. Prior observational studies have
noted that it takes several years for women who have complex atypical
hyperplasia to develop cancer.[13] However, up to 35% of women with complex
atypical hyperplasia will have an underlying malignancy in their hysterectomy
specimen.[14] For this reason, the definitive treatment for complex hyperplasia
with atypia is hysterectomy.
As the risk for developing endometrial cancer in women with hyperplasia
without atypia is low, it can be managed with progestin therapy. This may
4

include oral progesterone or progesterone-impregnated intrauterine devices
(IUD). Studies have noted regression of hyperplasia without atypia in up to 80%
of women treated with oral progesterone.[15, 16] Of interest, studies have noted
an increased rate of regression of complex hyperplasia without atypia in women
who utilize the IUD than in women treated with oral progesterone. However,
there was no significant difference in the rate of regression among women with
simple hyperplasia without atypia.[17] Figure 1 illustrates the difference
between benign endometrium, endometrial hyperplasia, and endometrial
adenocarcinoma under low power.
A

B

C

Figure 1: H&E Comparing Normal Endometrium to Hyperplasia and
Cancer. A) Proliferative endometrium. B) Complex atypical hyperplasia.
C) Endometrial Adenocarcinoma
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Obesity and Development of Endometrial Hyperplasia and Cancer
Obesity is one of the greatest risk factors for developing endometrial
hyperplasia or cancer. In fact, almost 50% of endometrial cancer cases may be
related to obesity.[18] Furthermore, increasing body mass index (BMI) leads to
increased risk. Lu and colleagues demonstrated that overweight women were
twice as likely and obese women up to five times as likely to develop endometrial
cancer as their normal-weight counterparts.[6] In fact, for each 5 kg/m2 increase
in BMI, there is a significant increase in risk of developing endometrial
cancer.[19]
In addition to being at increased risk for developing endometrial cancer,
obese women are at increased risk for dying from the disease.

Calle and

colleagues found that obese women were approximately 2.5 times more likely
and morbidly obese women were 6 times more likely than normal-weight women
to die from endometrial cancer.[20]

Additionally, obese endometrial cancer

patients are almost 3 times as likely to die from causes other than endometrial
cancer.[21]

This is likely secondary to the association of obesity with other

medical conditions, such as diabetes mellitus, hypertension, and cardiac disease.
The Role of Estrogen in the Development of Endometrial Cancer
Unopposed estrogen, whether exogenous or endogenous, is a well-known
risk factor for the development of endometrial hyperplasia and cancer. In the
1960’s, the first cases of endometrial cancer related to hormone replacement
therapy were reported.[22]

This observation has been validated in multiple
6

studies since that time.[23-25] Furthermore, the cancer risk has been found to
be associated with both dose and duration of estrogen use.[26, 27]
It has long been hypothesized that unopposed endogenous or exogenous
estrogen

leads

to the

development

of

endometrial cancer.

Though

premenpausal women make estrogen mostly in the ovaries, postmenopausal
women form estrogen only in peripheral tissue, including adipose tissue.

In

adipose tissue, aromatase converts androgens to estrone and estradiol (Figure
2).

Aromatase is an enzyme produced in the adipose tissue and levels are

increased in obesity.

The increased aromatase levels in combination with

decreased sex hormone binding globulin levels lead to increased circulating
estrogen levels in obese women. In fact, studies have demonstrated up to 40%
higher

estrogen

levels

in

postmenopausal women.[28]

obese

as

compared

with

normal-weight

Furthermore, studies have shown an association

between elevated estrogen concentration and endometrial cancer.[29, 30]
The mechanism by which excess unopposed estrogen leads to
endometrial hyperplasia and cancer is complex. In essence, however, estrogen
leads to increased mitotic activity in endometrial cells. This can cause DNA
replication errors and eventually mutations that result in the development of
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carcinoma.[31, 32] Estrogen is also involved in activation of kinase signaling
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Figure 2: Conversion of Androgens to Estrogens in Adipose Tissue.
Mechanism by which testosterones are converted to estrogens by the
enzyme aromatase in peripheral tissue.
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cascades, including the PI3 and MAP kinase pathways, via association between
estrogen receptors and cell surface receptors.[33]

These pathways lead to

cellular proliferation and aberrations in them are frequently found in endometrial
cancer.[34]
A model for the role of estrogen in the pathogenesis of endometrial cancer
has been proposed by Rizner in 2013.[35] In this hypothesis, estrogens are
synthesized in peripheral tissue (mainly adipose tissue), leading to increased
circulating levels of estrogens.

These estrogens are transported into the

endometrial cells, where they are metabolized into 4-hydroxyestrogens and 3,4quinones due to upregulation of the enzyme CYP1B1.

The 3,4-quinones

produced by this reaction induce formation of DNA adducts and reactive oxygen
species, which can cause mutations in tumor suppressor genes or oncogenes,
such as PTEN and K-RAS. These mutations lead to the development of cancer.
In these cancer cells, estrogen receptor is over-expressed (specifically, estrogen
receptor α), leading to more estrogen binding and proliferation of the mutated
cells. Of note, the Dr. Rizner is careful to point out that this hypothesis is based
on interpretation of the available literature and that further studies are warranted
to fully evaluate its accuracy.
Insulin Resistance and the Development of Endometrial Cancer
While the prevailing hypothesis is that unopposed estrogen is the driver of
endometrial cancer development, there is increasing evidence that insulin
resistance may also play a role. Insulin resistance is decreased sensitivity to
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insulin leading to increased blood glucose levels.[36]

Patients with insulin

resistance develop hyperinsulinemia to compensate for the hyperglycemic state.
This increased insulin concentration has been correlated with the development of
malignancies, including endometrial cancer. Several studies have associated
insulin resistance with endometrial cancer, even when controlling for obesity or
estrogen levels.[37-39]
Inflammatory mediators are believed to be some of the common
regulatory factors in both insulin resistance and the development of endometrial
cancer. In insulin resistance, inflammation recruits of macrophages to adipose
tissue via secretion of monocyte chemoattractant protein-1. By releasing tumor
necrosis factor-α, the macrophages activate the extracellular signal-related
kinase and c-Jun-N-terminal-kinase pathways, thereby inhibiting insulin signaling.
The macrophages also secrete interleukin-6, which is believed to play a role in
insulin resistance, though the exact mechanism is unknown.[36, 40-42]
Interleukin-6 is also known to lead to secretion of C-reactive protein, which is a
marker of inflammation and has been associated with endometrial cancer
risk.[43]
The hyperinsulinemia associated with insulin resistance has been
associated with the development of endometrial cancer. For example, in vitro,
endometrial cancer cell lines treated with insulin lead to decreased apoptosis and
increased cellular proliferation in a dose-dependent fashion. This finding is likely
secondary to activation of insulin receptor upon insulin binding, leading to
activation of the PI3K and MAPK pathways.[36, 44] The activated PI3K and
10

MAPK pathways can subsequently activate estrogen receptor, thereby leading to
unregulated cell growth and division.[45]

In fact, these pathways have been

associated with a large percentage of endometrial cancers.[46]
Hyperinsulinemia may also lead to endometrial cancer development
through indirect mechanisms. For example, insulin inhibits production of sex
hormone binding globulin, thereby causing increased blood levels of free sex
hormones, such as estrogens and androgens.[47] Furthermore, insulin promotes
androgen production by the ovaries. This allows for more free androgen to be
converted to estrogen in the peripheral tissues.
Insulin resistance can be difficult to study as there are many different
methods to measure it. These approaches include the QUICKI (1/[log fasting
insulin + log fasting glucose]), the insulin resistance index (fasting plasma
glucose x fasting insulin / 25), and the HOMA-IR index (fasting insulin x fasting
glucose / 22.5).[37-39] Unfortunately, there is no standard method to measure
insulin resistance and no universally accepted way to measure the relationship
between insulin resistance and endometrial cancer.
Given the association between insulin resistance and endometrial cancer,
there has been increasing interest in insulin-sensitizing agents as potential
therapies for endometrial cancer. Metformin is one of the agents that is being
investigated for this purpose.
endometrial

cancer

cell

In vivo, metformin has been found to inhibit

growth

through

mTOR

inhibition

and

AMPK

activation.[48] Other in vivo and in vitro studies have found that metformin may
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have the greatest effect in cells with K-Ras mutations.[49] Recently, a phase II
trial of everolimus and letrozole in patients with recurrent endometrial cancer
found a significantly higher response rate in patients who were also taking
metformin.[50] This unexpected finding led to the development of a phase II trial
of everolimus, letrozole, and metformin among women with recurrent endometrial
cancer, which is currently accruing patients (ClinicalTrials.gov identifier:
NCT01797523).
Adipokines
Historically, adipose tissue has been thought of as only insulation and a
storage site for energy. However, it is now known that adipose tissue is also an
endocrine organ that is involved in bone remodeling, immunity, and energy
homeostasis.[51]

Adipose tissue also secretes a class of cytokines called

adipokines. Multiple adipokines with varied functions that can act either locally or
systemically have been described (Table 3).
Adipokines have been associated with the development and progression
of multiple cancers, including breast, colon, pancreas, and endometrial.[52] This
is believed to occur through the activity of pro-inflammatory adipokines, which
stimulate cancer stem cells. This produces a feedback loop whereby there is
increased secretion of pro-inflammatory adipokines leading to tumor growth.[53]
Alternatively, some adipokines have been proposed as protective against cancer
development with decreased serum levels in patients with cancer.
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Adipokine
Adiponectin
Adipsin

Proposed Function(s)
Increases insulin sensitivity, Anti-inflammatory
Activates alternative complement pathway

Angiotensin II

Regulation of blood pressure

Apelin

Aid in control of energy stores

Appetite-Regulating Hormone

Aid in distribution and rate of energy use

Complement C1q TNF-Related

Increases insulin sensitivity, Anti-inflammatory

Protein 1
Aids with adipocyte differentiation and glucose

Chemerin

uptake

IL-6

Proinflammatory, Multiple functions

IL-8

Proinflammatory, Multiple functions

Leptin

Signals CNS regarding energy stores

Lipocalin 2
Monocyte Chemoattractant

Promotes insulin resistance
Proinflammatory, Promotes insulin resistance

Protein 1
Omentin

Anti-inflammatory

Plasminogen Activator Inhibitor

Inhibits plasminogen activation

1
Resistin
TNF-α

Increases insulin resistance
Reduces insulin sensitivity, Increases energy
consumption

Vaspin

Increases insulin sensitivity

Visfatin

Increases insulin sensitivity

Table 3: Select Adipokines and Proposed Functions [52, 54]. Selection of
some of the most commonly studied adipokines with their proposed function.
Adioponectin, an adipokine produced exclusively by adipocytes, has been
associated with insulin resistance and in the pathogenesis of endometrial cancer.

13

For example, in insulin resistance pathways, adiponectin has been noted to
activate AMP-activated protein kinase and peroxisome proliferator-activated
receptor-α. These enzymes decrease serum glucose concentration and increase
the expression of adiponectin and adiponectin receptors, leading to a positive
feedback loop.[36, 55]

Interestingly, serum adiponectin levels have been

inversely correlated with insulin levels.[56, 57] Serum adiponectin levels have
also been found to be lower in endometrial cancer patients than in women with
endometrial hyperplasia or normal endometrium.[58]

Other studies have

confirmed that adiponectin levels are decreased in endometrial cancer patients
as compared with controls and that elevated adiponectin levels are associated
with a lower risk of endometrial cancer.[59-61] Of note, adiponectin receptors
are expressed in both benign and malignant endometrial cancer cell lines, but
treatment with adiponectin in the malignant cell lines led to apoptosis.[62, 63]
This suggests a possible therapeutic application for adiponectin, but further
studies are needed.
Insulin resistance also appears to be mediated by leptin. This adipokine
inhibits insulin receptor and promotes the activity of other proteins that have been
associated with insulin resistance.[64, 65] The leptin receptor is also expressed
on multiple endometrial cancer cell lines and leptin may lead to increased
proliferation and invasion of these cells.[66, 67] The prognostic implications of
leptin are unclear as findings from clinical studies have been contradictory.
Small studies of serum leptin levels have found no difference between
endometrial cancer patients and controls.[68]

However, a meta-analysis that
14

included approximately 3,000 patients found elevated serum leptin to be an
independent risk factor for endometrial cancer.[69]
Omentin
Omentin, also known as intelectin, is a recently discovered adipokine that
is expressed by multiple tissues, including the heart, lungs, and ovary.[70]
However, omentin is preferentially secreted by the mesothelial cells of visceral
adipose tissue. There are two isoforms of omentin: omentin-1 and omentin-2.
However, omentin-1 is the major circulating isoform in human plasma. Omentin
is believed to be an insulin-sensitizing adipokine and aids with glucose uptake in
adipocytes as well as AKT signaling.[71]
It has been hypothesized that omentin has a role as an anti-inflammatory
agent since levels are generally decreased in patients with pro-inflammatory
conditions (Figure 3). For example, serum omentin levels are decreased among
patients with inflammatory bowel disease.[72]

Furthermore, there is some

evidence that decreased omentin levels may correlate with disease activity in
these patients.[73] Li and colleagues recently demonstrated that omentin levels
in synovial fluid of osteoarthritis patients are negatively correlated to disease
severity.[74]

Type 1 and type 2 diabetes mellitus are also associated with

decreased plasma omentin levels.[75, 76] This negative correlation remains true
when controlling for BMI.[76] Furthermore, treating omental adipose tissue with
insulin and glucose dose-dependently decreases omentin expression in this
tissue.[75]

15

Inflammatory Bowel Disease
- Serum omentin decreased
- Levels may serve as marker
for disease activity
Diabetes
- Serum omentin negatively
correlated with fasting insulin
- Levels decline with
worsening insulin resistance

Obesity
- Serum omentin decreased
- Weight loss increases levels
- Exercise increases levels

OMENTIN

PCOS
- Serum omentin decreased,
independent of obesity and
insulin resistance

Coronary Artery Disease
- Omentin levels decreased
- Levels may be inversely
associated with the severity of
disease

- Increased androgen levels
may contribute to decreased
omentin levels.
Arthritis
- Serum and synovial fluid
omentin
decreased
- Levels inversely correlated
with radiographic severity of
disease

Figure 3:

Omentin in Other Disease Processes.

Many pro-

inflammatory diseases have found an inverse correlation with omentin,
including obesity, diabetes, arthritis, PCOS, and inflammatory bowel
syndrome.
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Omentin levels have also been inversely correlated to BMI, waist
circumference, and other markers of obesity.[77] Interestingly, omentin levels
have been noted to increase with weight loss and aerobic exercise.[78, 79] Tan
and colleagues also demonstrated an increase in serum omentin levels after
treatment with metformin in women with polycystic ovarian syndrome
(PCOS).[80] However, this has not been evaluated in obesity.
The mechanism of omentin’s anti-inflammatory function is poorly
understood, though there is evidence that it may be via activation of AMPK and
inhibition of TNF-α. For example, Yamawaki and colleagues demonstrated that
omentin inhibits TNF-α-induced COX-2 expression in vascular endothelial cells.
It has been hypothesized that omentin is able to do this by inhibiting JNK via
activation of the AMPK/eNOS/NO pathway.[81, 82]
Omentin and Cancer
Cancer is also an inflammatory disease state, but few studies have
attempted to examine the relationship between omentin and cancer. In their
study of tissue from 196 patients with gastric cancer, Zheng and colleagues
found that more than 72% of tumors expressed intelectin (omentin). Additionally,
intelectin positivity of these tumors was inversely correlated with depth of
invasion, lymph node metastases, distant metastases, and clinical stage.[83]
Omentin levels were also noted to be decreased in patients with colorectal
cancer and the findings of one small study suggested that omentin may be able
to aid with prognosis in advanced stage colorectal cancer patients.[84, 85]
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Furthermore, omentin levels appear to be elevated after these patients complete
their therapy as compared with healthy controls.[86] Of interest, a recent study
of prostate cancer patients found that they had higher omentin levels than
patients with benign prostate disease. However, BMI and other confounders
were not controlled for and these results have not yet been validated.[87]
Unpublished work from our lab has noted that circulating omentin levels are
lower in women with ovarian cancer and higher levels have been correlated with
improved overall survival. These findings provide exciting promise for the use of
omentin as a potential prognostic biomarker in malignancies.

18

Hypotheses and Specific Aims
There are currently no studies evaluating omentin in endometrial
hyperplasia or endometrial cancer.

Given that these are both inflammatory

states associated with obesity and insulin resistance, it would be prudent to study
the role of omentin in this disease process.
The present study was intended to better understand the relationship
between omentin and endometrial hyperplasia and endometrial cancer with the
following specific aims:

•

Specific Aim 1: To evaluate the serum omentin levels of women
with complex atypical hyperplasia of the endometrium and
endometrioid endometrial adenocarcinoma as compared with
controls.
o Hypothesis:
women

with

Serum omentin levels will be decreased in
complex

atypical

hyperplasia

of

the

endometrium or endometrial adenocarcinoma, independent
of BMI or menopausal status.

•

Specific Aim 2: To assess the difference in serum omentin levels
among BMI groups in women with complex atypical hyperplasia of

19

the endometrium and endometrioid endometrial adenocarcinoma
as compared with controls.
o Hypothesis:

Serum omentin levels will be lower among

obese women with complex atypical hyperplasia of the
endometrium or endometrial adenocarcinoma as compared
with normal-weight women with these diseases.

20

Methods
Approvals
Approval for relevant studies was obtained from the University of Texas at
MD Anderson Cancer Center Institutional Review Board (IRB).
Statistical Considerations
Clinical characteristics and demographics were summarized with descriptive
statistics. Because this was a matched case-control study and data were paired,
the paired difference in omentin was measured between cancer cases and their
controls. Descriptive statistics were then utilized to summarize these differences.
A t-test was performed on the differences from zero within each BMI category.
The Wilcoxon rank sum test was then used to compare BMI groups with respect
to medians of these differences. A similar analysis was performed on the paired
difference in omentin between hyperplasia cases and controls.

A p-value of

<0.05 was considered statistically significant.
Clinical Analysis
A retrospective, laboratory-based case-control study was conducted to
compare the levels of omentin in women with endometrial adenocarcinoma or
endometrial hyperplasia (cases) to women with no history of cancer (controls).
After IRB approval was obtained, cases and controls were identified in the
University of Texas MD Anderson gynecologic oncology tumor bank. All women
with samples stored in the tumor bank provided informed consent to have their
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blood, urine, and tissue samples collected at the time of surgery and be stored
for future research.
To be included in the study, cases must have a confirmed diagnosis of
grade 1 endometrioid endometrial adenocarcinoma or complex atypical
hyperplasia with serum available in the tumor bank. Patients with type II tumors,
inadequate banked serum, or without available data in the clinical record were
excluded from the study. Women included in the control group must have no
history of endometrial hyperplasia or carcinoma with serum available in the tumor
bank. Additionally, controls were matched to the cases with respect to
menopausal status and BMI category (Table 4). Patients were excluded from the
control group if they had active cancer of any kind at the time of serum collection,
inadequate banked serum, or no available data in the clinical record.
Category
Underweight
Normal Weight
Overweight
Obese

BMI Range (kg/m2)
< 18.5
18.5 – 25
26 – 30
>30

Table 4: BMI Categories. Standarized classification of BMI.
In total 140 cancer cases and 72 hyperplasia cases were matched 1:1 to
controls by BMI and menopausal status. Clinical data for both cases and
controls was then obtained from the medical record, including age, ethnicity,
menopausal status, medical history, and pathology.
22

ELISA
Patient serum samples were initially obtained from centrifuged whole
blood and stored in a freezer at -800 Celsius before being thawed for the purpose
of this study. Serum omentin was measured in using a commercially available
enzyme-linked immunoadsorbent assay (ELISA) kit (BioVendor, Human
Omentin-1 ELISA, Czech Republic). The assay was performed in triplicate for
each sample and the mean concentration of omentin for each patient
determined.
Prior to beginning the assay, serum samples were diluted 1:40 using a
dilution buffer provided in the kit. The standards were prepared according to the
kit instructions to obtain omentin concentrations of 64 ng/mL, 32 ng/mL, 16
ng/mL, 8 ng/mL, 4 ng/mL, and 2 ng/mL. Quality controls were also prepared with
dilution buffer and assayed to ensure that the results were acceptable.

All

samples, standards, and quality controls were mixed with a vortex prior to
pipetting 100 µL of each into a 96-well plate.
After all samples were plated, the plate was incubated at 370 Celsius for
two hours without shaking. The wells were then removed from the incubator,
aspirated, and washed with 300 µL of wash solution (provided by the kit) three
times. After this wash, 100 µL of a biotin-labeled antibody solution (provided by
the kit) was pipetted into each well. The plate was then incubated at 370 Celsius
for 30 minutes without shaking.

The plate was again removed from the

incubator, aspirated, and washed three times with 300 µL of wash solution. Next,
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100 µL of streptavidin-HRP conjugate was pipetted into each well. The plate was
again incubated without shaking at 370 Celsius for 30 minutes. Upon removal
from the incubator, the plate was aspirated and washed three times with 300 µL
of wash solution. After completion of this wash, 100 µL of substrate solution was
added to each well. The plate was covered with aluminum foil and incubated at
room temperature for 10 minutes. After the incubation period, 100 µL of stop
solution was added to halt the color change.
Upon completion of the ELISA, the plate was read by a microplate reader
set to 450 nm with a reference wavelength of 630 nm. A standard curve was
calculated by subtracting the absorbance values for the wavelengths, plotting the
difference of absorbencies on the y-axis against the known concentration of the
standards on the x-axis. The x-axis was then set to a logarithmic scale. The
omentin concentration of the samples was obtained using the standard curve and
multiplying values by 40 to adjust for the dilution of the sample.
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Results
As demonstrated in table 5, cancer cases, hyperplasia cases, and controls
had similar demographic and clinical factors. Overall, almost three-fourths of
women were white, and this proportion was similar between groups. The mean
age was 58, though women in the hyperplasia group were slightly younger. The
BMI of each group was very similar, as expected given that the groups were
matched based upon BMI.
Characteristic

Cancer

Hyperplasia

Controls

Total

60 (±11.44)

53 (±12.29)

59 (±11.62)

58 (±11.62)

White

68.6 (96)

76.4 (55)

77.9 (120)

74 (271)

Black

4.3 (6)

2.8 (2)

7.8 (12)

5.5 (20)

Hispanic

20 (28)

16.7 (12)

10.4 (16)

15.3 (56)

Asian

7.1 (10)

4.2 (3)

3.9 (6)

5.2 (19)

Diabetes (n)

22.1 (31)

18.1 (13)

12.3 (19)

17.2 (63)

Metformin Use (n)

15.7 (22)

9.7 (7)

8.4 (13)

11.5 (42)

2.9 (4)

23.6 (17)

15.6 (24)

12.3 (45)

Mean Age (SD)
Ethnicity (n)

Breast Cancer History (n)

Table 5: Participant Characteristics. Characteristics are summarized by
group – cancer, hyperplasia, and controls. The hyperplasia group is younger
with less diabetes and metformin use. Ethnicity is similar across groups.
As anticipated, the mean serum omentin levels were significantly higher in
lean women (673 ng/mL) as compared to overweight (481 ng/mL) and obese
women (475 ng/mL) with p<0.000. This is demonstrated in figure 4.

25

p<0.0001

Figure 4: Mean Omentin Concentration by BMI Group. Omentin
levels were higher in lean patients as compared with overweight and
obese women.
As seen in figure 5, mean serum omentin levels were significantly lower in
women with endometrial cancer as compared with matched controls (576 ng/mL
vs 673 ng/mL, p=0.02). Furthermore, among women with endometrial
hyperplasia, the mean serum omentin concentration was significantly lower than
matched controls (359 ng/mL vs 723 ng/mL, p<0.001).
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p=0.02

p<0.001

Figure 5: Omentin Concentration in Cases versus Controls. Women
with endometrial cancer and hyperplasia had significantly lower omentin
than their matched controls.
When stratified by BMI, lean women with endometrial cancer had a
statistically lower serum omentin level than lean controls. However, there was no
difference in omentin concentration between overweight and obese endometrial
cancer patients and controls. When women with hyperplasia were evaluated,
there was a significantly lower serum omentin level in lean and obese cases
when compared with controls. However, there was no difference between
overweight hyperplasia cases and controls (table 6).
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Endometrial Cancer
N
Total

Omentin
(Mean)

Controls

SD

N

Omentin
(Mean)

p-value
SD

74

575.76

229.47

74

673.77

324.87

0.0204

< 25

21

667.73

241.60

21

954.06

317.46

<0.001

25 to 30

15

474.31

153.79

15

593.30

250.35

0.177

> 30

38

564.98

233.01

38

550.64

259.33

0.802

BMI (kg/m2)

Endometrial

Controls

Hyperplasia
N
Total

Omentin
(Mean)

SD

N

Omentin
(Mean)

p-value

SD

74

359.57

199.64

74

723.32

449.80 <0.0001

< 25

17

438.32

251.20

17

995.94

523.52

0.002

25 to 30

16

354.79

212.33

16

652.42

575.61

0.068

> 30

41

328.78

164.24

41

637.96

307.06

<0.001

BMI (kg/m2)

Table 6: Mean Serum Omentin in Cases vs Controls Stratified by BMI. Only
lean endometrial cancer patients have lower serum omentin than controls. Lean
and obese hyperplasia cases had lower omentin than controls.
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Discussion
Prior studies have consistently shown an inverse relationship between
omentin and obesity. De Souza Batista and colleagues demonstrated that serum
omentin levels are negatively correlated with BMI and waist circumference.[77]
It has also been noted that serum omentin is decreased in patients with
metabolic syndrome. In a population of Japanese men, omentin levels were
significantly lower in patients with large waist circumference, dyslipidemia,
elevated blood pressure, and impaired glucose tolerance.[88]

Interestingly,

weight loss has been shown to increase serum omentin levels and improve
insulin sensitivity.[78]
The present study is consistent with other researchers, confirming that
serum omentin concentration is inversely related to BMI. Interestingly, there is
not a strict negative correlation between omentin levels and BMI. For example,
while lean women were noted to have a significantly higher serum omentin than
overweight and obese women, there was no difference in omentin levels
between overweight and obese women.

The reasons for this are unclear.

However, many factors others than BMI may influence omentin levels (i.e. waist
circumference, amount of visceral vs peripheral fat, etc) and these confounders
may account for the results in our study.
There are currently no published studies evaluating the relationship
between omentin and endometrial cancer. In the present study, women with
endometrial adenocarcinoma have decreased serum omentin levels when
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compared with controls, as hypothesized.

However, when stratified by BMI,

there was only a difference in omentin levels between lean cases and controls.
Reasons for this finding are not clear.

However, it may be related to the

relatively small numbers in each BMI group and other confounders that affect
omentin levels.
The etiology of the relationship between omentin and endometrial cancer
has not yet been investigated.

However, it is likely multifactorial and may be

indirectly related to the inhibition of omentin’s anti-inflammatory effects. Multiple
studies in other disease processes have demonstrated omentin’s antiinflammatory properties. In patients with juvenile arthritis, for example, omentin
levels are lower among patients with active disease as compared with those with
disease in remission.[89] Patient’s with Crohn’s disease have also been found to
have lower omentin levels, and it appears that these lower levels are important to
disease activity.[90]

In vascular endothelial cells, omentin has been

demonstrated to inhibit COX-2 expression by activating the AMPK and eNOS
pathways, thereby decreasing inflammation.[82]
Other adipokines may also be indirectly involved in the process of
endometrial cancer development. Leptin was the first adipokine to be discovered
and is known to be associated with regulating appetite, weight, and
metabolism.[91] Elevated serum leptin levels have been associated with obesity
and endometrial carcinoma.[92]

Another adipokine, adiponectin, has similar

characteristics to omentin and has been shown to be inversely related to
endometrial cancer.[59, 93] An evaluation of patients with diabetes, impaired
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glucose tolerance, and normal glucose tolerance noted a positive correlation
between serum omentin levels and serum adiponectin levels.

Furthermore,

serum adiponectin was an independent predictor of serum omentin levels.[76]
The role of adipokines in the pathogenesis of endometrial cancer appears to be
complex and has not been completely elucidated.
How decreased levels of omentin directly affect endometrial cancer
development has not yet been studied.

However, the mechanism may be

extrapolated from work in other malignancies. For example, there is evidence
that omentin may activate apoptosis pathways. In hepatocellular carcinoma cell
lines, administration of omentin led to activation of the caspase-3 and JNK
pathways.[94] Other studies have suggested that omentin may play a role in
tumor suppression. In neuroblastoma, administration of intelectin-1 (omentin) led
to suppression of cell growth, invasion, and metastasis. This finding occurred
both in vitro and in vivo.[95] In ovarian cancer, unpublished data from our lab
has demonstrated that omentin can aid with decreased cell proliferation, motility,
and invasion potential.
The present study was the first to evaluate the relationship between
omentin and complex atypical hyperplasia of the endometrium. We found that
women with endometrial hyperplasia possessed significantly lower serum
omentin levels than controls.

When evaluated by BMI, lean and obese

hyperplasia cases had lower omentin levels than controls. As complex atypical
hyperplasia represents a precancerous condition, these results suggest that
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omentin may be related to the early changes in the endometrium that ultimately
lead to the development of cancer.
Of interest, the mean serum level of omentin in women with endometrial
hyperplasia was lower than that of women with endometrial cancer. The reasons
for this are unclear, as it would be expected that omentin levels in women with
endometrial hyperplasia would be lower than that of controls, but higher than
levels in women with endometrial cancer. However, it should be noted that with
a case-control design, the present study was not designed to directly compare
omentin levels between women with endometrial cancer and women with
hyperplasia. Each group was matched to its own set of controls but not one
another. Therefore, it is difficult to assess if a true difference in omentin levels
exists between the hyperplasia and cancer groups.
Our results further illuminate the intricate relationship between adipokines,
obesity, and endometrial cancer.

While we have confirmed an inverse

relationship between serum omentin levels and endometrial hyperplasia and
carcinoma, the etiology for the lower omentin levels in these patients is unknown.
It may be postulated that many endometrial cancer patients possess other risk
factors associated with decreased omentin, such as obesity, diabetes, and
PCOS. In these cases, it is likely that comorbidities led to decreased serum
omentin levels.

This, in turn, contributed to the development of endometrial

cancer via absence of the tumor suppressor mechanisms of omentin. However,
presumably many women with decreased omentin due to other risk factors never
develop endometrial cancer.

The etiology of this phenomenon should be
32

evaluated but may be related to downregulation of omentin expression by the
cancer cells. For example, unpublished work from our lab has noted that ovarian
cancer leads to decreased omentin mRNA expression in the mesothelial cells.
However, it should be remembered that endometrial cancer development is a
complex process and unlikely to be soley dependent on low serum omentin
levels. Further research is warranted to investigate this.
The clinical implications of our study findings are currently only theoretical.
For example, there is potential use of omentin as a biomarker for endometrial
hyperplasia and its progression to cancer. This may be especially true in lean
women, as this was the only group noted to have significantly lower omentin
levels in both hyperplasia and cancer cases when compared to controls. Also,
given that controls had higher serum omentin levels than cases, omentin may
have utility in endometrial cancer prevention trials. For example, it is known that
serum omentin levels increase with weight loss and exercise.[78] Additionally, in
studies of PCOS, administration of metformin led to increased serum omentin
levels.[80] These findings provide for exciting possibilities for clinical trials if they
hold true in women at high risk for endometrial cancer. Furthermore, there is
unpublished data from our lab demonstrating that serum omentin levels are
inversely correlated with survival in ovarian cancer patients.

This finding is

difficult to extrapolate to the low grade or early stage endometrial cancer
population as these women typically have excellent overall survival at baseline.
However, omentin may be a biomarker to predict survival or risk of recurrence in
women with high grade or advanced stage endometrial cancer.

Additional
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studies are warranted to explore this possibility. Finally, given that administration
of omentin to cancer cell lines leads to increased cell apoptosis and tumor
suppression, it may be that omentin itself has a therapeutic benefit. However,
the role of omentin administration in preventing or reversing endometrial
hyperplasia or cancer is unknown and needs to be further evaluated.
One of the main limitations of this study is its retrospective nature.
Furthermore, serum samples were obtained from an institutional tumor bank and
in some cases had been frozen for several years. Though omentin is believed to
be a very stable protein, determining omentin from fresh rather than frozen
samples may provide more consistent results. The relatively small number of
samples that we evaluated may also limit this study, though our study was
powered to detect a sufficient difference in omentin levels. Finally, there is a
wide number of clinical factors that may affect omentin levels other than obesity
(diabetes, cardiovascular disease, arthritis, etc). As it would be impossible to
control for each of these, it is likely that our results are limited by these
confounders.
Although it is clear that omentin is related to endometrial cancer and
hyperplasia regardless of BMI, the etiology of this relationship is unknown. As
such, it is difficult to determine what clinical implications the association between
endometrial cancer and omentin will provide.

Our results present exciting

promise for omentin’s role in further understanding the relationship between
obesity-related factors and endometrial cancer.
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